Start here if you're new
what it is
BXP owns big office-heavy buildings in six expensive cities and collects rent, plus some retail, apartments, and hotel income.
how it gets paid
Last year Bxp made $3.5B in revenue. Office & life sciences was the main engine at $3.08B, or 88% of sales.
why it's growing
Full-year revenue grew ~2.2%. Noisy quarterly vs. prior year lines (sometimes triple-digit % in EDGAR) reflect comparability and REIT reporting— do not stack them next to the steady FY growth rate without context.
what just happened
One print showed ~$0.18 GAAP EPS on lumpy revenue lines; pair with FFO and period labels— headline rent growth is still low single digits for the year.
At a glance
B+ balance sheet — decent shape, but not bulletproof
35/100 earnings predictability — expect surprises
71.6x trailing p/e — you're paying up for this one
5.5% dividend yield — cash in your pocket every quarter
4.0% return on capital — nothing to write home about
xvary composite: 39/100 — weak
What they do
BXP owns big office-heavy buildings in six expensive cities and collects rent, plus some retail, apartments, and hotel income.
BXP wins because it owns 163 office and life sciences buildings in six gateway markets where replacing a premier address is slow, expensive, and painful. If your company wants top space in Boston, New York, or San Francisco, you usually need an existing landlord with scale, local teams, and capital. That footprint gives BXP pricing power in the best corners of weak office markets.
How they make money
$3.5B
annual revenue · their business grew +2.2% last year
Office & life sciences
$3.08B
Retail assets
$0.27B
Residential properties
$0.13B
Hotel
$0.02B
The products that matter
owns and leases commercial properties
Office and Life Sciences Properties
$3.5B revenue · 163 buildings
It's the whole ~$3.5B story: trophy office and lab-oriented space with full-year revenue growth ~2.2% on this page, while FFO can still slip when expenses run hot. Rent growth alone is not enough.
entire business
Key numbers
71.6x
trailing p/e
You are paying a growth-stock multiple for a landlord with 2.2% revenue growth and 4.0% return on capital.
5.5%
dividend yield
The payout is the main reason to stay, because price appreciation looks limited against the $64 18-month target.
34.0%
operating margin
The buildings still throw off solid property-level profit, but rising expenses are eating into that cushion.
4.0%
return on capital
For every $100 tied up in the business, BXP earns about $4 back. That is a skinny return for prime real estate.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 60 / 100
- net profit margin 15.0% — keeps 15 cents of every dollar in revenue
- return on equity 10% — $0.10 profit for every $1 investors have put in
B+ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in BXP 3 years ago → it's now worth $12,330.
The index would have given you $13,920.
source: institutional data · total return
What just happened
beat estimates
Quarter revenue ~$870M with GAAP EPS ~$0.18 in one window— FFO and multi-quarter trends matter more than one volatile GAAP print.
Huge vs. prior year % moves in screen scrapes often mix periods (e.g. nine months vs quarter) or GAAP lines. Use the filing: full-year revenue pace here is ~low single digits, and FFO guidance can fall even when rent inches up.
~$870M
quarter revenue
~$0.18
GAAP EPS (Q)
59.2%
gross margin
the number that mattered
The durable read is low single-digit revenue growth with FFO pressure when expenses outrun rent— not a one-quarter vs. prior year headline from a data feed.
-
bxp, inc. will likely report uneven results for the full year soon ending. (the reit is set to release december-period financials in early february.) on the one hand, revenues increased 2.2% over the first nine months, from the same span last year, to a combined $2.61 billion.
-
decent operating metrics and nominal portfolio growth were the catalysts.
-
but, on the other, expenses (+3.2%) are rising faster than revenues, which is eroding margins.all told, funds from operations (ffo) slipped to an aggregate of $5.09 per share during the first three quarters, from $5.31 in the like-2024 stretch.
-
for full-year 2025, we expect revenues to advance about 2% to $3.48 billion, but ffo will likely retreat 3%–4%, to $6.85 per share.
-
office market fundamentals remain hit or miss.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the top threat is persistent weakness in high-end office leasing.
med
office demand stays soft
BXP owns 163 office and life sciences buildings. If tenants keep shrinking footprints or delaying leases, those high-quality addresses still feel the vacancy math.
This is a portfolio-level risk across essentially the full $3.5B revenue base.
med
costs keep outrunning rent growth
Recent operating pressure is already visible: expenses rose 3.2% while revenue grew 1% in the quarter setup.
That gap is how FFO per share slides from $5.31 to $5.09 even when revenue is still inching higher.
med
the yield story loses its cushion
A 5.5% dividend yield attracts income investors. It also raises the stakes if cash earnings weaken further.
When the stock is already at $71.62 versus a $64 analyst midpoint, a smaller margin for error can turn into a valuation air pocket fast.
When a $3.5B property portfolio is growing revenue 1% while expenses rise 3.2%, even modest leasing weakness can pressure FFO and the 5.5% income case at the same time.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
core FFO per share
$5.09 through the first three quarters is the key trend line. If that stabilizes, the whole story looks less fragile.
earnings
next quarterly report
The street expects $0.50 EPS and $0.9B of revenue. You want to see whether management can beat a very low bar cleanly.
risk
expense growth versus rent growth
Revenue up 1% and expenses up 3.2% is the wrong direction. If that spread persists, the yield will have to do all the work.
trend
price versus analyst midpoint
The stock is at $71.62 while the midpoint target is $64. Either analysts are behind the move, or the shares ran ahead of the fundamentals.
Analyst rankings
short-term outlook
bottom 5%
momentum score 5 — the weakest bucket. In human-speak, one analyst model thinks near-term performance could be rough.
risk profile
average
stability score 3. Translation: this is not a bunker stock, but it is not a chaos stock either.
chart momentum
top 20%
technical score 2 — the tape looks better than the fundamentals. Welcome to why ranking systems sometimes disagree.
earnings predictability
35 / 100
The business is harder to forecast than the average blue-chip income name. That fits an office REIT in a messy market.
source: institutional data
Institutional activity
institutions have been net buying for 3 consecutive quarters — 293 buyers vs. 271 sellers in 3q2025. total institutional holdings: 0.2B shares. net buying for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$40
$88
$72
current price
$64
target midpoint · 11% from current · 3-5yr high: $130 (+80% · 19% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive